Smith & Nephew (LON:SN) Receives Hold Rating from Berenberg Bank

Berenberg Bank reiterated their hold rating on shares of Smith & Nephew (LON:SN) in a report published on Friday morning, MarketBeat reports. Berenberg Bank currently has a GBX 1,300 price target on the stock.

SN has been the subject of a number of other research reports. Citigroup boosted their target price on shares of Smith & Nephew from GBX 1,450 to GBX 1,600 and gave the stock a “buy” rating in a research report on Friday, October 31st. Panmure Gordon reissued a “hold” rating and set a GBX 1,200 price objective on shares of Smith & Nephew in a research report on Tuesday, December 9th. JPMorgan Chase & Co. restated an “overweight” rating on shares of Smith & Nephew in a research note on Friday, November 7th. Finally, Royal Bank Of Canada downgraded Smith & Nephew to a “sector perform” rating and dropped their price target for the stock from GBX 1,700 to GBX 1,350 in a research report on Wednesday, December 17th. Two analysts have rated the stock with a Buy rating and four have issued a Hold rating to the company. Based on data from MarketBeat.com, the company has a consensus rating of “Hold” and a consensus target price of GBX 1,381.33.

Smith & Nephew Trading Down 0.8%

Shares of Smith & Nephew stock opened at GBX 1,225.50 on Friday. The company has a debt-to-equity ratio of 70.22, a current ratio of 2.51 and a quick ratio of 0.84. The business has a fifty day moving average price of GBX 1,235.01 and a two-hundred day moving average price of GBX 1,283.14. The firm has a market capitalization of £13.43 billion, a PE ratio of 44.12, a price-to-earnings-growth ratio of 0.46 and a beta of 0.62.

Insider Transactions at Smith & Nephew

In other Smith & Nephew news, insider Deepak Nath sold 1,240 shares of the company’s stock in a transaction that occurred on Tuesday, November 11th. The stock was sold at an average price of GBX 1,257, for a total value of £15,586.80. 0.19% of the stock is owned by corporate insiders.

About Smith & Nephew

Smith & Nephew plc, together with its subsidiaries, develops, manufactures, markets, and sells medical devices and services in the United Kingdom and internationally. It operates through three segments: Orthopaedics, Sports Medicine & ENT, and Advanced Wound Management. The company offers knee implant products for knee replacement procedures; hip implants for revision procedures; trauma and extremities products that include internal and external devices used in the stabilization of severe fractures and deformity correction procedures; and other reconstruction products.